238 related articles for article (PubMed ID: 29016511)
1. Change in Surgical Practice for Women With Leiomyomas After the U.S. Food and Drug Administration Morcellator Safety Communication.
Clark NM; Schembri M; Jacoby VL
Obstet Gynecol; 2017 Nov; 130(5):1057-1063. PubMed ID: 29016511
[TBL] [Abstract][Full Text] [Related]
2. Association of the U.S. Food and Drug Administration Morcellation Warning With Rates of Minimally Invasive Hysterectomy and Myomectomy.
Barron KI; Richard T; Robinson PS; Lamvu G
Obstet Gynecol; 2015 Dec; 126(6):1174-1180. PubMed ID: 26595561
[TBL] [Abstract][Full Text] [Related]
3. Practice patterns and postoperative complications before and after US Food and Drug Administration safety communication on power morcellation.
Harris JA; Swenson CW; Uppal S; Kamdar N; Mahnert N; As-Sanie S; Morgan DM
Am J Obstet Gynecol; 2016 Jan; 214(1):98.e1-98.e13. PubMed ID: 26314519
[TBL] [Abstract][Full Text] [Related]
4. Racial Disparities in Response to a US Food and Drug Administration Safety Communication Regarding the Use of Power Morcellation for the Treatment of Uterine Leiomyoma.
Matsushita T; Sekizawa A; Jacobs LK
J Minim Invasive Gynecol; 2020 Jan; 27(1):178-185.e1. PubMed ID: 30936031
[TBL] [Abstract][Full Text] [Related]
5. Risk of morcellation of uterine leiomyosarcomas in laparoscopic supracervical hysterectomy and laparoscopic myomectomy, a retrospective trial including 4791 women.
Lieng M; Berner E; Busund B
J Minim Invasive Gynecol; 2015; 22(3):410-4. PubMed ID: 25460521
[TBL] [Abstract][Full Text] [Related]
6. What is the Future of Open Intraperitoneal Power-Morcellation of Fibroids?
Parker WH; Pritts EA; Olive DL
Clin Obstet Gynecol; 2016 Mar; 59(1):73-84. PubMed ID: 26670834
[TBL] [Abstract][Full Text] [Related]
7. U.S. Food and Drug Administration's Guidance Regarding Morcellation of Leiomyomas: Well-Intentioned, But Is It Harmful for Women?
Parker WH; Kaunitz AM; Pritts EA; Olive DL; Chalas E; Clarke-Pearson DL; Berek JS;
Obstet Gynecol; 2016 Jan; 127(1):18-22. PubMed ID: 26646134
[TBL] [Abstract][Full Text] [Related]
8. Risk of Undetected Cancer at the Time of Laparoscopic Supracervical Hysterectomy and Laparoscopic Myomectomy: Implications for the Use of Power Morcellation.
Perkins RB; Handal-Orefice R; Hanchate AD; Lin M; Paasche-Orlow MK
Womens Health Issues; 2016; 26(1):21-6. PubMed ID: 26701205
[TBL] [Abstract][Full Text] [Related]
9. Changes in Myomectomy Practice After the U.S. Food and Drug Administration Safety Communication on Power Morcellation.
Stentz NC; Cooney LG; Sammel M; Shah DK
Obstet Gynecol; 2017 Jun; 129(6):1007-1013. PubMed ID: 28486366
[TBL] [Abstract][Full Text] [Related]
10. Use of Electric Power Morcellation and Prevalence of Underlying Cancer in Women Who Undergo Myomectomy.
Wright JD; Tergas AI; Cui R; Burke WM; Hou JY; Ananth CV; Chen L; Richards C; Neugut AI; Hershman DL
JAMA Oncol; 2015 Apr; 1(1):69-77. PubMed ID: 26182307
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Morcellation Techniques at the Time of Laparoscopic Hysterectomy and Myomectomy.
Meurs EAIM; Brito LG; Ajao MO; Goggins ER; Vitonis AF; Einarsson JI; Cohen SL
J Minim Invasive Gynecol; 2017; 24(5):843-849. PubMed ID: 28483536
[TBL] [Abstract][Full Text] [Related]
12. Morcellation of occulted sarcomas during laparoscopic myomectomy and hysterectomy for patients with large fibroid uterus.
Tinelli A; Farghaly SA
Minerva Ginecol; 2018 Feb; 70(1):84-88. PubMed ID: 28975775
[TBL] [Abstract][Full Text] [Related]
13. The impact of recent power morcellator risk information on inpatient surgery and patient outcomes.
Schuttringer E; Beleche T
J Comp Eff Res; 2020 Jan; 9(1):53-65. PubMed ID: 31840551
[No Abstract] [Full Text] [Related]
14. Temporal trends in minimally invasive myomectomy before and after the US Food and Drug Administration recommendation against electric morcellation.
Pereira N; Frankel WC; Hutchinson AP; Patel HH; Mostisser C; Elias RT
Int J Gynaecol Obstet; 2017 Jun; 137(3):295-300. PubMed ID: 28218964
[TBL] [Abstract][Full Text] [Related]
15. The Sydney Contained In Bag Morcellation technique.
McKenna JB; Kanade T; Choi S; Tsai BP; Rosen DM; Cario GM; Chou D
J Minim Invasive Gynecol; 2014; 21(6):984-5. PubMed ID: 25048565
[TBL] [Abstract][Full Text] [Related]
16. Laparoscopic Power Morcellation: Techniques to Avoid Tumoral Spread.
Zapardiel I; Boria F; Halaska MJ; De Santiago J
J Minim Invasive Gynecol; 2021 Aug; 28(8):1442-1443. PubMed ID: 32961359
[TBL] [Abstract][Full Text] [Related]
17. Electric morcellation-related reoperations after laparoscopic myomectomy and nonmyomectomy procedures.
Pereira N; Buchanan TR; Wishall KM; Kim SH; Grias I; Richard SD; Della Badia CR
J Minim Invasive Gynecol; 2015 Feb; 22(2):163-76. PubMed ID: 25218993
[TBL] [Abstract][Full Text] [Related]
18. Practice Patterns and Complications of Benign Hysterectomy Following the FDA Statement Warning Against the Use of Power Morcellation.
Multinu F; Casarin J; Hanson KT; Angioni S; Mariani A; Habermann EB; Laughlin-Tommaso SK
JAMA Surg; 2018 Jun; 153(6):e180141. PubMed ID: 29641835
[TBL] [Abstract][Full Text] [Related]
19. Containment Bag Use Among Women Who Undergo Hysterectomy With Laparoscopic Power Morcellation.
Wright JD; Chen L; Melamed A; Clair CMS; Hou JY; Khoury-Collado F; Gockley A; Accordino M; Hershman DL; Xu X
Obstet Gynecol; 2022 Sep; 140(3):371-380. PubMed ID: 35926199
[TBL] [Abstract][Full Text] [Related]
20. Hysterectomy Practice Patterns in the Postmorcellation Era.
Jorgensen EM; Modest AM; Hur HC; Hacker MR; Awtrey CS
Obstet Gynecol; 2019 Apr; 133(4):643-649. PubMed ID: 30870280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
